Toxicon : official journal of the International Society on Toxinology · 2026
Ziyuglycoside I Attenuates Deinagkistrodon acutus Venom-Induced Injury in Renal Tubular Epithelial Cells by Modulating PAR1-NLRP3-IL-1β Signaling.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shen Yiwei, Jiang Naiqi, Tu Mengyun
Аннотация
INTRODUCTION: Sanguisorba officinalis L. (Di Yu) has traditionally been used for snakebite treatment. Ziyuglycoside I, a major bioactive constituent of Di Yu, exhibits anti-inflammatory activity, but its role in snake venom-associated renal injury remains unclear. This study aimed to investigate its potential protective effects against Deinagkistrodon acutus venom (DAV)-induced renal tubular epithelial cell injury in vitro.
METHODS: HK-2 cells were exposed to DAV to establish an in vitro renal tubular epithelial injury model. Cellular metabolic activity and intracellular ATP levels were assessed using Cell Counting Kit-8 and CellTiter-Glo assays, respectively. DAV-induced molecular alterations were examined by transcriptomic sequencing, bioinformatic analysis, western blotting, and qRT-PCR. PAR1 knockdown and pharmacological inhibition with vorapaxar were performed to determine the role of PAR1. Ziyuglycoside I was then applied to evaluate its effects on DAV-induced injury, PAR1 expression, and PAR1 ubiquitination.
RESULTS: DAV dose-dependently reduced cellular metabolic activity and intracellular ATP levels in HK-2 cells, accompanied by inflammatory and apoptosis-related responses, altered cellular energy metabolism, increased NLRP3 and IL-1β expression, and decreased Bcl-2 expression. PAR1 knockdown or inhibition attenuated DAV-induced inflammatory activation and cellular injury. Ziyuglycoside I alleviated DAV-induced HK-2 cell injury, reduced PAR1 and IL-1β protein expression, and enhanced PAR1 ubiquitination, with evidence supporting proteasome-associated regulation of PAR1 protein levels.
CONCLUSION: Ziyuglycoside I may exert an in vitro protective effect against DAV-induced HK-2 cell injury, possibly by enhancing PAR1 ubiquitination and reducing PAR1 protein levels through a proteasome-associated mechanism, thereby suppressing PAR1-NLRP3-IL-1β-associated inflammatory responses.
METHODS: HK-2 cells were exposed to DAV to establish an in vitro renal tubular epithelial injury model. Cellular metabolic activity and intracellular ATP levels were assessed using Cell Counting Kit-8 and CellTiter-Glo assays, respectively. DAV-induced molecular alterations were examined by transcriptomic sequencing, bioinformatic analysis, western blotting, and qRT-PCR. PAR1 knockdown and pharmacological inhibition with vorapaxar were performed to determine the role of PAR1. Ziyuglycoside I was then applied to evaluate its effects on DAV-induced injury, PAR1 expression, and PAR1 ubiquitination.
RESULTS: DAV dose-dependently reduced cellular metabolic activity and intracellular ATP levels in HK-2 cells, accompanied by inflammatory and apoptosis-related responses, altered cellular energy metabolism, increased NLRP3 and IL-1β expression, and decreased Bcl-2 expression. PAR1 knockdown or inhibition attenuated DAV-induced inflammatory activation and cellular injury. Ziyuglycoside I alleviated DAV-induced HK-2 cell injury, reduced PAR1 and IL-1β protein expression, and enhanced PAR1 ubiquitination, with evidence supporting proteasome-associated regulation of PAR1 protein levels.
CONCLUSION: Ziyuglycoside I may exert an in vitro protective effect against DAV-induced HK-2 cell injury, possibly by enhancing PAR1 ubiquitination and reducing PAR1 protein levels through a proteasome-associated mechanism, thereby suppressing PAR1-NLRP3-IL-1β-associated inflammatory responses.